Jeffrey Vietri
Overview
Explore the profile of Jeffrey Vietri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
671
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liang C, Begier E, Hagel S, Ankert J, Wang L, Schwarz C, et al.
J Infect
. 2025 Feb;
90(3):106440.
PMID: 39952477
Background: RSV is a leading cause of ARI, including CAP, in older adults. Data available often underestimate RSV-related ARI incidence. We estimated RSV-related ARI hospitalization incidence from a prospective CAP...
2.
Cho J, Lee H, Wannaadisai W, Vietri J, Chaiyakunapruk N
Vaccine
. 2024 Dec;
46():126656.
PMID: 39731806
Background: The economic and public health benefits of adult pneumococcal vaccines vary across countries due to different epidemiology and costs. We systematically reviewed and summarized findings and assumptions of cost-effectiveness...
3.
Vietri J, Maculaitis M, Cappelleri J, Yu H, Kopenhafer L, Beusterien K
Vaccine
. 2024 Sep;
42(24):126261.
PMID: 39217776
Introduction: Clostridioides difficile (C.diff) infection (CDI) causes significant morbidity and mortality among older adults. Vaccines to prevent CDI are in development; however, data on the target population's preferences are needed...
4.
Nakamura S, Mikami M, Hayamizu T, Yonemoto N, Moyon C, Gouldson M, et al.
Expert Rev Vaccines
. 2024 May;
23(1):546-560.
PMID: 38703180
Background: The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is used in the Japanese National Immunization Program for older adults and adults with increased risk for pneumococcal disease, however, disease incidence and...
5.
Hanquet G, Theilacker C, Vietri J, Sepulveda-Pachon I, Menon S, Gessner B, et al.
Infect Dis Ther
. 2024 Mar;
13(4):921-940.
PMID: 38498108
Introduction: Estimating the burden of lower respiratory tract infections (LRTIs) increasingly relies on administrative databases using International Classification of Diseases (ICD) codes, but no standard methodology exists. We defined best...
6.
Kuhne F, Achtert K, Puschner F, Urbanski-Rini D, Schiller J, Mahar E, et al.
Expert Rev Vaccines
. 2023 Oct;
22(1):921-932.
PMID: 37881844
Objectives: Despite national recommendations for use of pneumococcal vaccines, rates of community-acquired pneumonia (CAP) and invasive pneumococcal disease (IPD) remain high in Germany. New pneumococcal conjugate vaccines (PCVs) with expanded...
7.
Marbaix S, Mignon A, Taelman A, Averin A, Atwood M, Vietri J
Expert Rev Vaccines
. 2023 Oct;
22(1):1008-1021.
PMID: 37872765
Background: The Belgian Superior Health Council (SHC) preferentially recommended the 20-valent pneumococcal conjugate vaccine (PCV20) for adults aged ≥65 years, immunocompromised patients, and patients aged ≥50 years suffering from conditions...
8.
Gourzoulidis G, Barmpouni M, Kossyvaki V, Vietri J, Tzanetakos C
Front Public Health
. 2023 Oct;
11:1229524.
PMID: 37841729
Objective: Higher valency pneumococcal conjugate vaccines (PCVs) are expected to improve protection against pneumococcal disease through coverage of additional serotypes. The aim of the present study was to evaluate the...
9.
Chilson E, McGrath L, Alfred T, Vietri J
Am J Prev Med
. 2023 Sep;
66(1):164-168.
PMID: 37673196
Introduction: Recommendations for adult pneumococcal vaccination in the U.S. were revised in 2022 after the introduction of 15- and 20-valent pneumococcal conjugate vaccines (PCV15 and PCV20) to call for routine...
10.
Vietri J, Sato R, Averin A, Weycker D, Kumar M, Prasad S, et al.
Vaccine
. 2023 Jul;
41(36):5211-5215.
PMID: 37474408
Background: In November 2019, the US Advisory Committee on Immunization Practices recommended shared clinical decision-making (SCDM) for use of 13-valent pneumococcal conjugate vaccine (PCV13) among immunocompetent elderly adults. The impact...